AAPL315.34-0.88 (-0.28%) ▼|ABBV250.91+2.13 (+0.86%) ▲|ABT105.23-0.29 (-0.27%) ▼|ACN175.80-3.23 (-1.80%) ▼|ADBE254.86-2.40 (-0.93%) ▼|AMAT468.85-3.94 (-0.83%) ▼|AMD521.10+15.36 (+3.04%) ▲|AMGN391.27-1.90 (-0.48%) ▼|AMT175.43-0.30 (-0.17%) ▼|AMZN252.40-4.57 (-1.78%) ▼|AVGO364.38-4.18 (-1.13%) ▼|AXP321.80-4.30 (-1.32%) ▼|BA206.42-4.31 (-2.05%) ▼|BAC62.67+0.28 (+0.45%) ▲|BKNG173.43-6.87 (-3.81%) ▼|BLK1,072.03-23.34 (-2.13%) ▼|BMY64.41-0.28 (-0.43%) ▼|BNY162.51-0.34 (-0.21%) ▼|BRK-B506.72+0.89 (+0.18%) ▲|C137.80+1.06 (+0.78%) ▲|CAT815.56-6.92 (-0.84%) ▼|CL88.03-0.38 (-0.43%) ▼|CMCSA24.59-1.74 (-6.61%) ▼|COF210.86-3.10 (-1.45%) ▼|COP136.53+1.49 (+1.10%) ▲|COST902.60-7.58 (-0.83%) ▼|CRM244.16-4.96 (-1.99%) ▼|CSCO109.43+0.26 (+0.24%) ▲|CVS95.38-0.69 (-0.72%) ▼|CVX213.81+4.01 (+1.91%) ▲|DE677.21-3.52 (-0.52%) ▼|DHR204.85-0.38 (-0.19%) ▼|DIS104.18-0.88 (-0.84%) ▼|DUK120.43-0.81 (-0.67%) ▼|EMR150.34-1.81 (-1.19%) ▼|FDX309.19-4.94 (-1.57%) ▼|GD352.67-3.91 (-1.10%) ▼|GE325.42-9.49 (-2.83%) ▼|GEV951.04-20.27 (-2.09%) ▼|GILD145.65-0.99 (-0.68%) ▼|GM83.76-2.03 (-2.37%) ▼|GOOG328.38-7.00 (-2.09%) ▼|GOOGL330.65-7.71 (-2.28%) ▼|GS1,028.78-7.75 (-0.75%) ▼|HD310.45-3.25 (-1.04%) ▼|HON204.93-3.31 (-1.59%) ▼|IBM239.94+7.85 (+3.38%) ▲|INTC106.24+1.77 (+1.69%) ▲|INTU313.94-4.99 (-1.56%) ▼|ISRG353.24+3.08 (+0.88%) ▲|JNJ267.08-2.04 (-0.76%) ▼|JPM354.71+1.20 (+0.34%) ▲|KO87.55-0.81 (-0.92%) ▼|LIN466.65-1.73 (-0.37%) ▼|LLY1,124.21+0.30 (+0.03%) ▲|LMT524.46-11.69 (-2.18%) ▼|LOW198.60-2.20 (-1.10%) ▼|LRCX315.84-4.58 (-1.43%) ▼|MA567.50-3.39 (-0.59%) ▼|MCD253.48-2.33 (-0.91%) ▼|MDLZ62.42+0.79 (+1.28%) ▲|MDT91.89-0.50 (-0.54%) ▼|META653.69+40.21 (+6.55%) ▲|MMM164.40-3.12 (-1.86%) ▼|MO67.89-0.28 (-0.41%) ▼|MRK147.53-0.93 (-0.63%) ▼|MS215.35-0.89 (-0.41%) ▼|MSFT491.65-2.30 (-0.47%) ▼|MU1,027.77+27.51 (+2.75%) ▲|NEE82.65-1.18 (-1.41%) ▼|NFLX76.03-0.74 (-0.96%) ▼|NKE37.35-0.75 (-1.97%) ▼|NOW131.11-3.10 (-2.31%) ▼|NVDA223.67-2.06 (-0.91%) ▼|ORCL161.63-0.89 (-0.55%) ▼|PEP136.69-1.76 (-1.27%) ▼|PFE27.78-0.01 (-0.04%) ▼|PG142.64-2.94 (-2.02%) ▼|PLTR169.53-0.77 (-0.45%) ▼|PM185.71+0.98 (+0.53%) ▲|QCOM176.40+2.31 (+1.33%) ▲|RTX197.55-1.26 (-0.63%) ▼|SBUX100.04-1.97 (-1.93%) ▼|SCHW106.54-0.33 (-0.31%) ▼|SO88.34-0.65 (-0.73%) ▼|SPG204.53-5.10 (-2.43%) ▼|T25.15-0.45 (-1.76%) ▼|TMO605.69+2.67 (+0.44%) ▲|TMUS177.34-4.35 (-2.39%) ▼|TSLA367.81-0.35 (-0.10%) ▼|TXN261.59+2.67 (+1.03%) ▲|UBER71.08-2.05 (-2.80%) ▼|UNH393.06-7.78 (-1.94%) ▼|UNP284.74-3.71 (-1.29%) ▼|UPS99.22-1.26 (-1.25%) ▼|USB62.11-0.38 (-0.61%) ▼|V367.39-1.25 (-0.34%) ▼|VZ49.74-0.67 (-1.33%) ▼|WFC89.67+1.71 (+1.94%) ▲|WMT105.83-0.22 (-0.21%) ▼|XOM164.23+3.57 (+2.22%) ▲|AAPL315.34-0.88 (-0.28%) ▼|ABBV250.91+2.13 (+0.86%) ▲|ABT105.23-0.29 (-0.27%) ▼|ACN175.80-3.23 (-1.80%) ▼|ADBE254.86-2.40 (-0.93%) ▼|AMAT468.85-3.94 (-0.83%) ▼|AMD521.10+15.36 (+3.04%) ▲|AMGN391.27-1.90 (-0.48%) ▼|AMT175.43-0.30 (-0.17%) ▼|AMZN252.40-4.57 (-1.78%) ▼|AVGO364.38-4.18 (-1.13%) ▼|AXP321.80-4.30 (-1.32%) ▼|BA206.42-4.31 (-2.05%) ▼|BAC62.67+0.28 (+0.45%) ▲|BKNG173.43-6.87 (-3.81%) ▼|BLK1,072.03-23.34 (-2.13%) ▼|BMY64.41-0.28 (-0.43%) ▼|BNY162.51-0.34 (-0.21%) ▼|BRK-B506.72+0.89 (+0.18%) ▲|C137.80+1.06 (+0.78%) ▲|CAT815.56-6.92 (-0.84%) ▼|CL88.03-0.38 (-0.43%) ▼|CMCSA24.59-1.74 (-6.61%) ▼|COF210.86-3.10 (-1.45%) ▼|COP136.53+1.49 (+1.10%) ▲|COST902.60-7.58 (-0.83%) ▼|CRM244.16-4.96 (-1.99%) ▼|CSCO109.43+0.26 (+0.24%) ▲|CVS95.38-0.69 (-0.72%) ▼|CVX213.81+4.01 (+1.91%) ▲|DE677.21-3.52 (-0.52%) ▼|DHR204.85-0.38 (-0.19%) ▼|DIS104.18-0.88 (-0.84%) ▼|DUK120.43-0.81 (-0.67%) ▼|EMR150.34-1.81 (-1.19%) ▼|FDX309.19-4.94 (-1.57%) ▼|GD352.67-3.91 (-1.10%) ▼|GE325.42-9.49 (-2.83%) ▼|GEV951.04-20.27 (-2.09%) ▼|GILD145.65-0.99 (-0.68%) ▼|GM83.76-2.03 (-2.37%) ▼|GOOG328.38-7.00 (-2.09%) ▼|GOOGL330.65-7.71 (-2.28%) ▼|GS1,028.78-7.75 (-0.75%) ▼|HD310.45-3.25 (-1.04%) ▼|HON204.93-3.31 (-1.59%) ▼|IBM239.94+7.85 (+3.38%) ▲|INTC106.24+1.77 (+1.69%) ▲|INTU313.94-4.99 (-1.56%) ▼|ISRG353.24+3.08 (+0.88%) ▲|JNJ267.08-2.04 (-0.76%) ▼|JPM354.71+1.20 (+0.34%) ▲|KO87.55-0.81 (-0.92%) ▼|LIN466.65-1.73 (-0.37%) ▼|LLY1,124.21+0.30 (+0.03%) ▲|LMT524.46-11.69 (-2.18%) ▼|LOW198.60-2.20 (-1.10%) ▼|LRCX315.84-4.58 (-1.43%) ▼|MA567.50-3.39 (-0.59%) ▼|MCD253.48-2.33 (-0.91%) ▼|MDLZ62.42+0.79 (+1.28%) ▲|MDT91.89-0.50 (-0.54%) ▼|META653.69+40.21 (+6.55%) ▲|MMM164.40-3.12 (-1.86%) ▼|MO67.89-0.28 (-0.41%) ▼|MRK147.53-0.93 (-0.63%) ▼|MS215.35-0.89 (-0.41%) ▼|MSFT491.65-2.30 (-0.47%) ▼|MU1,027.77+27.51 (+2.75%) ▲|NEE82.65-1.18 (-1.41%) ▼|NFLX76.03-0.74 (-0.96%) ▼|NKE37.35-0.75 (-1.97%) ▼|NOW131.11-3.10 (-2.31%) ▼|NVDA223.67-2.06 (-0.91%) ▼|ORCL161.63-0.89 (-0.55%) ▼|PEP136.69-1.76 (-1.27%) ▼|PFE27.78-0.01 (-0.04%) ▼|PG142.64-2.94 (-2.02%) ▼|PLTR169.53-0.77 (-0.45%) ▼|PM185.71+0.98 (+0.53%) ▲|QCOM176.40+2.31 (+1.33%) ▲|RTX197.55-1.26 (-0.63%) ▼|SBUX100.04-1.97 (-1.93%) ▼|SCHW106.54-0.33 (-0.31%) ▼|SO88.34-0.65 (-0.73%) ▼|SPG204.53-5.10 (-2.43%) ▼|T25.15-0.45 (-1.76%) ▼|TMO605.69+2.67 (+0.44%) ▲|TMUS177.34-4.35 (-2.39%) ▼|TSLA367.81-0.35 (-0.10%) ▼|TXN261.59+2.67 (+1.03%) ▲|UBER71.08-2.05 (-2.80%) ▼|UNH393.06-7.78 (-1.94%) ▼|UNP284.74-3.71 (-1.29%) ▼|UPS99.22-1.26 (-1.25%) ▼|USB62.11-0.38 (-0.61%) ▼|V367.39-1.25 (-0.34%) ▼|VZ49.74-0.67 (-1.33%) ▼|WFC89.67+1.71 (+1.94%) ▲|WMT105.83-0.22 (-0.21%) ▼|XOM164.23+3.57 (+2.22%) ▲|

24.6 C

New York

Thursday, September 10, 2026

/C O R R E C T I O N — Partillion Bioscience/

Holdun Family Office (Bahamas) Limited Confirms the Conclusion of its Licensed Wealth Management Business

Drivvr AI Welcomes Automotive Marketing Veteran Brian Voss as National Sales Director

Tag: blood

Vascarta Receives FDA Orphan Drug Designation for Vasceptor® in the Treatment of Sickle Cell Disease

SUMMIT, N.J., June 12, 2025 /PRNewswire/ -- Vascarta Inc., a biopharmaceutical company committed to advancing innovative therapies for underserved patient populations, announced today that...

Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements

1-for-60 reverse stock split to become effective as of the opening of trading on June 16, 2025

Vytanutra Launches Sustained Release Vitamin C with Iron for Daily Immune Support

IRVINE, Calif., June 12, 2025 /PRNewswire/ -- Vytanutra proudly announces the release of its newest product, Vytanutra C, Ascorbic Acid a scientifically formulated supplement designed...

Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025

Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL) post first-line therapy with a 24-month disease-free survival (DFS)...

MolecuLight® Imaging Significantly Improves Outcomes and Cuts Costs for Deep Sternal Wound Infections in Taiwan Study; Signals Expansion into Surgical Applications

PITTSBURGH and TAIPEI, June 12, 2025 /PRNewswire/ - MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, and its Taiwanese distributor,...

Enterome raises $19 million to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular Lymphoma

Paris, France – June 12, 2025

Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, has raised $19 million in a new private financing to advance its lead clinical program EO2463 OncoMimics™ immunotherapy to treat indolent non-Hodgkin lymphoma (iNHL). The new funds will be used to expand and finalize the ongoing Phase 1/2 SIDNEY clinical trial of EO2463 and prepare the candidate for a registrational trial.

Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect...

Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free survival versus acalabrutinib plus venetoclax¹

Multiple Sclerosis Market to Grow Rapidly at a CAGR of 3.8% During the Forecast Period (2025-2034) | DelveInsight

The multiple sclerosis market is growing due to rising prevalence, earlier diagnosis, and wider access to care. Demand is fueled by advancements in DMTs...

Result of General Meeting

June 11, 2025

Dance Icon Julianne Hough Partners with Icelandic Glacial™ in Brand’s First Major Celebrity Partnership

Partnership to Amplify the Brand's "You Are What You Drink, Be Exceptional" Message LOS ANGELES, June 11, 2025 /PRNewswire/ -- Icelandic Glacial™, the naturally alkaline,...

PESG Research Update: PolyPid SHIELD’s II Delivers Transformative Phase 3 Topline Results – Paradigm Shift in Surgical Infection Prevention

PESG issues a new briefing following PolyPid’s clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid’s D-PLEX100 as Potential New Standard of Care in the Future

PESG issues a new briefing following PolyPid’s clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid’s D-PLEX100 as Potential New Standard of Care in the Future

TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient

First patient in Cohort B achieved CR after 2nd dose of TCB008EDINBURGH, Scotland, June 11, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC (NASDAQ: TCBP), a...

AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical’s SCD Therapy to Advance Breakthrough...

$2 million in DoD funding enables the evaluation of SeaStar Medical’s SCD therapy in the setting of severe burns, inhalation injury, and sepsis

$2 million in DoD funding enables the evaluation of SeaStar Medical’s SCD therapy in the setting of severe burns, inhalation injury, and sepsis

ColonBroom GLP-1 Booster Website Updated to Highlight Daily Supplement for Metabolic Health

New website update showcases natural GLP-1 support supplement designed to curb cravings, support metabolism, and promote healthy weight management

New website update showcases natural GLP-1 support supplement designed to curb cravings, support metabolism, and promote healthy weight management

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsBlood